Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Eriksson, BI; Borris, LC; Dahl, OE; Haas, S; Huisman, MV; Kakkar, AK; Misselwitz, F; Muehlhofer, E; Kälebo, P 
Titel:
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. 
Abstract:
INTRODUCTION: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention of thromboembolic disorders. The aim of this study was to demonstrate proof-of-principle for rivaroxaban. MATERIALS AND METHODS: This was an open-label, dose-escalation study to assess the efficacy and safety of rivaroxaban, relative to enoxaparin, for the prevention of venous thromboembolism (VTE) after total hip replacement surgery. Patients were randomized in a 3:1 r...    »
 
Zeitschriftentitel:
Thromb Res 
Jahr:
2007 
Band / Volume:
120 
Heft / Issue:
Seitenangaben Beitrag:
685-93 
Sprache:
eng 
Print-ISSN:
0049-3848 
TUM Einrichtung:
r experimentelle Onkologie und Therapieforschung